Earlier studies have shown that a point mutation in human endostatin at position 125 (human endostatin wherein proline 125 was substituted with alanine, P125A-endostatin) improves endothelial cell binding and antiangiogenic activity. In the present study, we investigated the effect of recombinant adeno-associated virus (rAAV)-mediated gene delivery of P125A-endostatin (rAAV-P125Aendo) in a mouse model of ovarian carcinoma. Intramuscular (i.m.) injection of rAAVP125Aendo resulted in a dose-dependent increase in serum endostatin levels. Consequently, vascular endothelial growth factor-and basic fibroblast growth factor-mediated angiogenesis was significantly inhibited in mice injected with rAAV-P125Aendo as compared to control mice injected with rAAV-LacZ. Furthermore, gene therapy using rAAV-P125Aen-do construct showed sustained secretion of P125A-endostatin for up to 9 weeks after a single i.m. administration. Recombinant AAV-P125Aendo injection significantly inhibited the growth of human ovarian cancer cells in athymic nude mice. Immunofluorescence studies of residual tumors surgically removed from the rAAV-P125Aendo-treated animals showed decreased number of vessel ends and vessel length, indicating inhibition of angiogenesis. These studies suggest that recombinant AAV-mediated antiangiogenic gene therapy methods can be used to inhibit ovarian cancer growth. Gene Therapy (2005) 12, 30-38.
Introduction
A vast majority of human ovarian cancers arise from the single layer of epithelium surrounding the ovaries. Tumor growth is confined to ovary at early stages and later on spread into the peritoneal cavity. Ovarian cancer is often associated with development of malignant ascites. Ovarian cancer is a leading cause of death among the gynecological cancers 1 as patients are often diagnosed late in disease progression. Even after optimal surgical debulking and aggressive chemotherapy, 85% of patients show recurrence of the disease. Mortality rate of ovarian cancer patients in 5 years is about 50%. 2 Therefore, alternate methods of treatment are sought to treat ovarian cancer.
Etiology of ovarian cancer is not completely understood, but as in other solid tumor malignancies, this aggressive intraperitoneal malignancy is angiogenesisdependent 3, 4 and secretion of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) is of prognostic value. 5, 6 VEGF plays a critical role in the formation of malignant ascites in ovarian cancer. 7, 8 Malignant ascites is a main cause of morbidity in patients with intra-abdominal dissemination of various neoplasms, including ovarian cancer. 9 Some of the new strategies to treat ovarian cancer include inhibition of angiogenesis using endostatin, 10 angiostatin, 11 and interleukin-4. 12 Endostatin is a 20 kDa C-terminal proteolytic fragment of collagen XVIII. Endostatin has been shown to inhibit tumor growth in many model systems. 13, 14 Recently, we cloned and characterized a mutant endostatin, which had a single amino-acid substitution at the position 125. A nonconservative change of proline to alanine resulted in better binding to endothelial surface and antiangiogenic activity when compared to the native protein. Mutated human endostatin inhibited the spontaneous development of mammary cancer in C3 (1)/Tag mice. 15 P125A-endostatin (human endostatin wherein proline 125 was substituted with alanine) inhibits endothelial cell (EC) proliferation and migration better than the native protein. 15, 21 In the present study, we evaluated the effect of rAAV-mediated delivery of the mutated endostatin in a mouse model of ovarian cancer. P125A-endostatin cDNA was cloned in the rAAV vector and IgG kappa chain leader sequence was engineered as a secretory signal. A single injection of rAAV-P125Aendo resulted in sustained secretion of biologically active endostatin and inhibited angiogenesis in the Matrigel assays. Furthermore, intramuscular (i.m.) injection of rAAV-P125Aendo inhibited ovarian cancer growth in athymic nude mice, suggesting potential clinical use of rAAV-mediated P125A-endostatin gene therapy.
Results

Construction and characterization of rAAV-P125Aendo
cDNA fragment corresponding to a mutant human endostatin containing a substitution of proline to alanine at position 125 was cloned into pAAV-MCS vector. DNA sequence of the construct matched to the mutated endostatin, which was earlier cloned into Pichia pastoris expression system. Data in Figure 1 show characterization of secreted P125A-endostatin from pAAV-P125Aen-do-transfected cells. Conditioned media from the cells transfected with AAV-LacZ was used as a control. Culture supernatants from recombinant pAAV-P125Aen-do-transfected cells, however, showed significant levels of endostatin. From three independent measurements about 200 ng of endostatin was secreted into the culture medium in 48 h by one million cells. pAAV-LacZtransfected cells showed no detectable amounts of endostatin in ELISA. Mass spectrum analysis of the heparin-sepharose purified P125A-endostatin showed a major peak corresponding to 20.6 kDa ( Figure 1 ). We further characterized the purified protein by SDS-PAGE followed by Western blot analysis. Results showed presence of a 20 kDa band (Figure 1 inset) . For comparison, recombinant P125A-endostatin expressed in Pichia pastoris was used. Amino-terminal sequencing of first 10 residues completely matched with the NH 2 -terminal of human endostatin. These studies suggested that the leader sequence was correctly processed before the secretion of P125A-endostatin into culture supernatant.
Determination of biological activity
Two bioassay systems were used to determine the effect of mutated endostatin secreted by pAAV-P125Aendo-transfected cells. In vitro biological activity of the P125A-endostatin purified from the conditioned media was tested in human umbilical vein endothelial cell (HUVE cell) proliferation and migration assays. Data in Figure 2a show the ability of mutated endostatin to inhibit HUVE cell proliferation in vitro. Recombinant human basic fibroblast growth factor (bFGF)-induced proliferation of ECs was inhibited in a dose-dependent manner by P125A-endostatin. At 0.3 mg/ml, there was 29% inhibition of EC proliferation. Complete inhibition was seen at 1.5 mg/ml of purified mutated endostatin. In a second assay system, bFGF-induced migration of ECs was determined using Boyden chambers. These results are shown in Figure 2b . When compared to control cells, addition of bFGF induced cell migration by about fourfold. Migration of ECs was completely inhibited by 1.5 mg/ml of P125A-endostatin (P ¼ 0.01). 
Inhibition of angiogenesis in vivo
In order to determine whether rAAV-mediated delivery of mutated endostatin produced sufficient antiangiogenic effect, VEGF/bFGF-induced angiogenesis assay was used. Groups of athymic nude mice were inoculated with different doses of rAAV-P125Aendo. After 8 weeks, mice were subcutaneously (s.c.) injected with Matrigel preparations containing human VEGF165/bFGF on contralateral sites (six Matrigel plugs/dose). After 1 week, Matrigel plugs were surgically removed to evaluate vascularization. In parallel, serum samples obtained from the mice were analyzed for endostatin levels using an ELISA kit. Data in Figure 3 show the serum levels of endostatin. The endostatin levels in the mice varied depending on viral dose. Mice injected with 5 Â 10 9 viral particles (v.p.) showed a mean level of 24 ng/ml (P ¼ 0.02) and 1 Â 10 9 v.p. injected mice had 20 ng/ml (P ¼ 0.05). At a lower dose of 5 Â 10 8 v.p., about 5 ng/ml of endostatin was observed. Control mice showed no detectable levels of endostatin (detection limit of the assay -1.95 ng/ml). Mice injected with 1 Â 10 8 v.p. showed 2.3 ng/ml and 1 Â 10 7 v.p. showed a mean level of 5 ng/ml of endostatin. However, the levels of endostatin expressed in these two groups were not statistically significant when compared to the control mice due to large standard deviation.
Frozen sections of Matrigel plugs were stained with rat anti-mouse CD31-phycoerythrin (PE) conjugate. Images acquired from these studies were then morphometrically analyzed for vessel density by a previously published method. 16 Data in Figure 4 show effects of rAAV-P125Aendo treatment on vessel length, ends and branch points (nodes). There was a correlation between serum endostatin levels and antiangiogenic activity. Higher numbers of v.p. showed more pronounced inhibition of vessel ends, nodes and length. For example, the number of vessel branch points were decreased by 50% of control values by 5 Â 10 8 v.p. Higher viral load almost completely inhibited the number of vessel branch points (18.5% of control). Similarly, total vessel length was inhibited in a dose-dependent manner. Maximum inhibition (55%) was seen in the Matrigel plugs of mice injected with 1 Â 10 9 v.p. These studies demonstrated that rAAV-mediated expression of P125A-endostatin leads to potent antiangiogenic effects in vivo.
Inhibition of tumor growth
Athymic nude mouse model was used to investigate whether rAAV-P125Aendo-mediated gene therapy could inhibit tumor growth. Female, athymic nude mice (6-8 weeks old) (five animals/group) were injected with 2 Â 10 6 MA148 cells s.c. After 2 days, mice were injected with either 1 Â Antiangiogenic gene therapy of ovarian carcinoma IV Subramanian et al rAAV-P125Aendo-injected mice. The mean tumor volume of the control animals was 910 mm 3 when compared to rAAV-P125Aendo-injected animals, which showed a mean tumor volume of 252 mm 3 ( Figure 5 ). At the end of the experiment, mice were terminally bled and serum samples were collected. rAAV-P125Aendo-injected mice showed a mean serum level of 13 ng/ml (Figure 5b ). Residual tumors from control and rAAVP125Aendo-treated mice were surgically removed and analyzed for vessel density using morphometric methods. Figure 6 shows representative images of tumors from a control and rAAV-P125Aendo-treated mice. Top panels show CD31-positive EC-lined blood vessels in tumor sections. Corresponding skeletonized images of vessel tracings are shown in the bottom panels. Morphometric analyses of CD-31 staining showed significant inhibition in tumor vasculature in rAAV-P125Aendo-treated mice. Number of vessel nodes, ends and length were inhibited in rAAV-P125Aendo-treated animals when compared to rAAV-LacZ-treated mice ( Figure 7 ). For example, the rAAV-LacZ-injected mice showed a mean number of 240 nodes when compared to rAAVP125Aendo-treated mice, which showed a mean number of 128 vessel nodes ( Figure 7 ) (P ¼ 0.02). Similarly, total vessel length and number of vessel ends were inhibited by 40 and 34%, respectively, in the rAAV-P125Aendo-treated mice (P ¼ 0.01). The histology of the tissue sections from the liver, lung and muscle (site of v.p. injection) showed that rAAV injection did not have any adverse effects on normal tissues (Figure 8 ). Residual tumor tissues, however, showed necrosis and reduced vascularity in rAAV-P125Aendo-treated mice.
These studies demonstrate that rAAV can be used to express mutated endostatin in mice. rAAV-mediated gene therapy resulted in dose-dependent increase in Antiangiogenic gene therapy of ovarian carcinoma IV Subramanian et al serum levels of endostatin. As a consequence, angiogenesis was inhibited in vivo. Parallel studies showed that ovarian cancer growth can be inhibited by a single injection of rAAV-P125Aendo v.p., suggesting that such gene therapy methods will be useful in treating ovarian cancer.
Discussion
A number of viral and nonviral delivery systems have been used for gene therapy of ovarian cancer. 17 Deisseroth et al 18 reported the first gene therapy trials for ovarian cancer using safety-modified retroviral vector to protect the hematopoietic progenitor cells from highdose chemotherapy. Other studies used replicationdefective adenovirus to deliver wild-type p53 as an intraperitoneal infusion to inhibit ovarian cancer growth. However, phase I/II trials of rAd/p53 gene in the recurrent ovarian, primary peritoneal or fallopian tube cancer containing aberrant or mutant p53 19 were not very successful. A number of factors may have contributed to its failure: (a) inability to deliver wild-type p53 into all tumor cells, (b) lack of downstream apoptotic signaling molecules such as apoptotic protease-activating factor 1 (APAF 1), (c) immune reaction, (d) fibroid cysts preventing virus distribution in the peritoneal cavity and (e) transient expression of p53 transgene. In contrast to this approach, antiangiogenic therapies offer a number of advantages. Most importantly, antiangiogenic molecules can be delivered into a small fraction of tumor or normal cells. Since the secreted products will have a global effect on tumor neovascularization, it is expected to be more effective than the replacement gene therapies and suicide gene therapy strategies. 20 Furthermore, ECs constitute a small fraction when compared to total number of tumor cells. Therefore, even partial inhibition of EC proliferation would have a greater impact on tumor growth.
Human endostatin is a proteolytic fragment of NC-1 domain of type XVIII collagen. 10 Endostatin is an effective antiangiogenic molecule. Recently, we described a mutant endostatin, which contained a nonconservative substitution of proline to alanine at position 125. 21 While this mutation did not affect protein folding or gross secondary structure, it showed improved binding to ECs. As a consequence, the mutant protein inhibited EC migration, proliferation and angiogenesis more effectively when compared to the native molecule. 15, 21 Preliminary studies suggest that the mutation could alter binding profile of endostatin towards cell surface integrins (unpublished). Structural modifications altering the biological activity can be beneficial in improving therapeutic efficacy. In this context, we evaluated the gene delivery approaches to express P125A-endostatin in athymic nude mice.
AAV was used for delivering the endostatin gene in a mouse tumor model as it provides long-term expression of the transgene. Also for the antiangiogenic gene therapy, slow and continuous release of the protein is more important than high levels of expression. 22 A limited number of previous studies have shown that AAV can be used to express native endostatin in mice. Some of these studies have shown reduced angiogenesis and tumor growth following successful expression of the transgene. In other studies however, transgenic endostatin expression failed to show expected biological response. For example, mice injected with endostatintransduced hematopoietic stem cells had high levels of 
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IV Subramanian et al endostatin levels in the serum. In spite of higher circulating levels of endostatin, there was no inhibition of tumor growth when these mice were challenged with T241 fibrosarcoma cells. 23 In another study, a single dose of 1 Â 10 9 v.p. of rAAV-human endostatin (rAAV-HuEndo) was able to inhibit tumor growth and angiogenesis. 24 In these studies, the virus was injected 6 weeks before injecting the HT29 colon cancer cell lines. We injected the rAAV-P125Aendo 48 h after the s.c. implantation of tumor cells. Under these conditions, tumors would have been well established prior to rAAV-mediated expression of endostatin. Our studies showed that the endostatin levels in the serum of mice injected with 1 Â 10 9 v.p. of rAAV-P125Aendo was 20 ng/ml, which is comparable to 35-40 ng/ml of human endostatin observed in earlier studies. In a very recently published work, rAAVmediated delivery of human angiostatin and endostatin using a bicistronic vector led to improved inhibition of Antiangiogenic gene therapy of ovarian carcinoma IV Subramanian et al s.c. ovarian cancer growth in athymic mice. In this study, about 300-fold higher number of v.p. were used, 25 which resulted in 200 ng/ml of endostatin in circulation. Even though, P125A-endostatin levels were 10-fold less in the present study, there was comparable inhibition of tumor growth. Increased EC binding and biological activity caused by the mutation can be attributed to the relative improvement in potency of P125A-endostatin gene therapy. Mutant endostatin expression was dose dependent. Expression levels correlated to differences in antiangiogenic activities. A thorough analysis of angiogenesis using computer-assisted morphometric methods showed proportional differences in antiangiogenic response at higher doses. Vessel length and branch points were significantly inhibited in mice injected with 1 Â 10 9 v.p. At a similar dose, rAAV-P125Aendo gene therapy proved to be effective in inhibiting ovarian cancer growth significantly. Detectable levels of endostatin were seen at the end of experiment, Day 52. At this time, tumors were beginning to grow in the treatment group. Serum levels showed significant levels of endostatin in circulation. Repeated inoculation of rAAVP125Aendo at higher doses may be necessary to sustain higher serum levels of P125A-endostatin and prolonged inhibition of tumor growth.
Alternatively, antiangiogenic gene therapy methods should be complemented with conventional chemotherapy and radiotherapy. It is possible that well-established tumors with mature blood vessels may not be sensitive to endostatin therapy alone. Therefore, methods to improve biological activity of endostatin along with sustained delivery and improved expression strategies are useful for a successful treatment. rAAV-mediated delivery of endostatin enhances the treatment efficacy of ionizing radiation. 26 Likewise, tumor cells become more sensitive to chemotherapeutic agents after infection with AAV. 27, 28 Therefore, it would be interesting to see whether the chemotherapy along with rAAV-P125Aendo delivery would have a synergetic effect in treatment of ovarian carcinomas. Future studies will focus on preclinical development of antiangiogenic gene therapy approaches in combination with chemotherapy to treat ovarian cancers.
Materials and methods
Cell culture
MA-148, a human epithelial ovarian carcinoma, was grown in RPMI-1640 medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS (Cellgro, Mediatech, Washington, DC, USA) and 1% penicillinstreptomycin (Cellgro, Mediatech, Washington, DC, USA). E1A/E1B-transformed adherent 293 human embryonic kidney cells (Ad HEK293 cells) (Stratagene, La Jolla, CA, USA) were grown in DMEM medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS and 1% penicillin-streptomycin and 2 mmol/l L-glutamine (Life Technologies, Grand Island, NY, USA). HUVE cells provided by Dr Vercellotti (University of Minnesota, Minneapolis, MN, USA) were grown in tissue culture flasks precoated with 0.2% gelatin (Sigma, St Louis, MO, USA) and maintained in complete EGM medium (Clonetics, San Diego, CA, USA).
Recombinant AAV vector construction and purification pAAV-P125Aendo was constructed by PCR using a cDNA of the mutant human endostatin (P125A) that had been previously cloned into pPICZ alpha vector (Pichia expression system). The following primers were used for PCR amplification: upstream -AAA ACT GGT GAC GCG GCC CAG CAC AGC CAC; downstream -GGG AAG CTT CTA GGA GGC AGT CAT GAA GCT. An IgG kappa chain secretory signal was engineered at the 5 0 -end. First 10 cycles of PCR was carried out at 941C denaturation for 1 min, annealing at 551C and chain extension at 721C for 1 min each. For the remaining 20 cycles, the annealing temperature was raised to 601C. Final extension was carried out at 721C for 10 min. PCR amplified fragment was then cloned at BamHI-HindIII restriction sites of pAAV-MCS (Stratagene, La Jolla, CA, USA). pAAV-LacZ served as a control.
Recombinant AAV virus was produced by transfection of 80% confluent Ad HEK293 cells with three AAV vectors, namely, pAAV-MCS plasmid with either LacZ or P125A-endostatin, pHelper (carrying adenovirus derived genes VA, E2A and E4) and pAAV-RC (carrying AAV-2 replication and capsid gene) using CaCl 2 method. After 68 h of transfection, cells were lysed by three cycles of freeze-thaw, and treated with Benzonase (50 U/ml) (Sigma Chemical Company, St Louis, MO, USA) for 30 min at 371C. The cell debris was removed by centrifugation at 3000 g for 20 min at 41C. Virus was further purified using ammonium sulfate precipitation. After ammonium sulfate precipitation, the viral pellet was resuspended in 2.5 ml of phosphate-buffered saline (PBS) (pH 7.4) and then underlayed with an equal volume (2.5 ml) of Optiprep (Sigma, St Louis, MO, USA) density-gradient solution. Ultracentrifugation was carried out at 60 000 rpm for 4 h at 161C. In all, 15 fractions of 0.3 ml were collected from the bottom of the tube. The virus stock was dialyzed against PBS (pH 7.4) and concentrated using Biomax-100 concentrator, UFV2BHK10 (Millipore, Bedford, MA, USA). The v.p. were then titrated using slot blot analysis 29 and real-time PCR 30 as described earlier.
Characterization of the secreted protein
Ad HEK 293 cells were transduced either with pAAVP125Aendo or pAAV-LacZ along with pAAV-RC and pHelper plasmids. The levels of endostatin expressed in the culture supernatant were determined by endostatin immunoassay kit (Accucyte, Cytimmune Sciences Inc., College Park, MD, USA). Endostatin secreted into the culture supernatant was affinity purified using heparinsepharose column. Bound protein was eluted using 300 mM NaCl. Conditioned media from the Ad HEK 293 cells either transfected with rAAV-P125Aendo or rAAV-LacZ along with the purified P125A-endostatin from the conditioned media were run on a 15% SDS-PAGE. Western blotting was carried out using a rabbit anti-human endostatin antiserum and goat anti-rabbit IgG-HRP conjugate (Sigma Chemical Company, St Louis, MO, USA). The bands were detected using ECL autoradiography (Amersham Pharmacia Biotech, UK). Purified protein from rAAV-P125Aendo-infected cultures was used for Mass spectral analysis and amino-terminus sequencing.
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Inhibition of EC proliferation in vitro
Endothelial proliferation assay was performed as described earlier, 10 with minor modifications. Briefly confluent HUVE cells were trypsinized and seeded at 5000 cells/well in 96-well plates (precoated with 0.2% gelatin) in M199 media with 5% FBS. After 24 h, P125A-endostatin (1.5 mg/ml) purified from the culture supernatant was added to different wells in triplicate. After 20 min, 50 ng/ml of bFGF was added. Positive control wells had only bFGF and the negative control wells had neither bFGF nor endostatin. EC proliferation was determined 72 h later by 5-bromo-2 0 deoxyuridine (BrdU) incorporation into DNA by ELISA (Roche Molecular Biochemicals, Indianapolis, IN, USA). BrdU incorporation in positive control wells was considered as 100% proliferation to calculate relative inhibition elicited by P125A-endostatin treatment.
Inhibition of EC migration in vitro
The migration of the ECs was determined by using Boyden chambers (Neuro Probe, Gaithersburg, MD, USA), as described earlier, 31 with following modifications. HUVE cells were harvested in PBS containing 2 mM EDTA and prelabeled with a fluorescence dye, 5.0 mM 5(6)-CFDA for 10 min at 371C. Labeled cells were then preincubated with purified P125A-endostatin (1.5 mg/ml) for 60 min at 371C. Polycarbonate filters (pore size: 12 mm) were coated with 0.2% gelatin. bFGF (25 ng/ml) was added to lower chambers. HUVE cells (200 000 cells/ml, control and treated) were added to upper chambers. After 4 h of incubation at 371C, ECs remaining on the upper surface of the membrane were removed with a cell scraper, and the cells migrated to the bottom of the membrane were fixed in 3% formaldehyde and counted. Fluorescence images were recorded using a digital camera, under Â 200 magnification for counting.
Matrigel plug neovascularization assay
In vivo angiogenesis assay was carried out using bFGF/ VEGF165-stimulated Matrigel assay. Group of three athymic nude mice were injected i.m. with different doses of rAAV-P125Aendo 5 Â 10 9 , 1 Â 10 9 , 5 Â 10 8 and 1 Â 10 8 v.p. At 8 weeks after injecting v.p., mice were implanted s.c. on both sides of the flank with 500 ml of Matrigel preparations (BD Biosciences, Bedford, MA, USA) containing 200 ng/ml of human VEGF165 (R&D Systems, Minneapolis, MN, USA), 100 ng/ml of bFGF (R&D Systems, Minneapolis, MN, USA) and 100 U/ml of heparin (Sigma Chemical Company, St Louis, MO, USA). Matrigel plugs were surgically removed 7 days after implantation, to evaluate microvessel density. Frozen sections (10 mm) of Matrigel plugs were fixed in cold acetone and stained with anti-mouse CD31-PE conjugate to visualize blood vessels. In parallel, sera obtained from the mice were analyzed for endostatin levels using Accucyte ELISA, (Cytimmune Sciences Inc., College Park, MD, USA).
Animal studies
Exponentially growing MA 148 ovarian cancer cells were harvested by trypsinization, washed twice with Hanks' balanced salt solution (HBSS, Cellgro, Mediatech, Washington, DC, USA) and resuspended at 2 Â 10 7 cells/ ml in serum-free RPMI-1640 medium. An aliquot of 100 ml of the suspension was then injected s.c. into the flanks of 6-8 weeks old, female, athymic nude mice (N ¼ 5) (NCI, Bethesda, MD, USA). After two days, mice were injected i.m. either with 100 ml of 1 Â 10 9 v.p. of rAAV-LacZ or rAAV-P125Aendo. Tumor growth was monitored by caliper measurements and tumor volume was calculated by the formula a Â b 2 /2, where 'a' represents the larger diameter and 'b' represents the smaller diameter of the tumor. At the end of the experiment, serum samples were collected from mice for determining endostatin levels using the Accucyte ELISA (Cytimmune Sciences Inc., College Park, MD, USA).
Vessel staining and histological studies
A part of the tumor specimens and Matrigel plugs were snap-frozen in liquid nitrogen. Frozen samples were then cut into 10-mm thick sections and stored at À801C until further analysis. For immunofluorescence studies to localize blood vessels, tissue specimens were slowly brought to room temperature, air-dried and subsequently fixed in chilled acetone for 10 min. The slides were then allowed to air dry for 1 h and were washed for 5 min in PBS (pH 7.4). The samples were then blocked with PBS containing 3% bovine serum albumin for 30 min at room temperature and subsequently incubated with a PE-conjugated monoclonal antibody to mouse CD-31 (1:50 dilution, Pharmingen, San Diego, CA, USA) for 30 min at room temperature. Slides were washed three times with PBS (pH 7.4) and immediately imaged in an Olympus BX-60 fluorescence microscope at Â 200 magnification as described previously. 16 Nuclei were stained with DAPI before imaging. Part of the tissue samples (tumor, muscle, liver and kidney) were also fixed in 10% formalin and processed for H&E staining.
Determination of angiogenic response
A morphometric analysis method, which was originally developed in our laboratory 16 to determine blood vessel architecture was used to determine the extent of angiogenic response. Briefly, digital images were acquired from fluorescence microscope using Metamorph image analysis software (Image 1, Westchester, PA, USA). About seven to 10 independent images from the two sections from each sample were obtained and then biniarized using Adobe Photoshop (Adobe Inc., Mountain View, CA, USA). After inverting (black to white) the images, vessel architecture, that is, length, branch points and ends were calculated by 'skeletonization' of the images by using the Image Processing Toolkit (RGI Inc., Raleigh, NC, USA). Statistical significance was calculated by the Student's t-test.
